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Helicobacter pylori infection is the major cause of gastroduodenal pathologies, but only a minority of infected patients develop
gastric B-cell lymphoma, gastric autoimmunity, or other life threatening diseases, as gastric cancer or peptic ulcer. The type of
host immune response against H. pylori, particularly the cytolytic eﬀector functions of T cells, is crucial for the outcome of the
infection. T cells are potentially able to kill a target via diﬀerent mechanisms, such as perforins or Fas-Fas ligand interaction. In
H. pylori-infected patients with gastric autoimmunity cytolytic T cells, that cross-recognize diﬀerent epitopes of H. pylori proteins
and H+K+-ATPase autoantigen, infiltrate the gastric mucosa and lead to gastric atrophy via long-lasting activation of Fas ligand-
mediated appotosis and perforin-induced cytotoxicity. On the other hand, gastric T cells from MALT lymphoma exhibit defective
perforin- and Fas-Fas ligand-mediated killing of B cells, with consequent abnormal help for B-cell proliferation, suggesting that
deregulated and exhaustive H. pylori-induced T cell-dependent B-cell activation can support both the onset and the promotion of
low-grade B-cell lymphoma.
1. Introduction
Helicobacter pylori is a Gram-negative gastrointestinal bac-
terium that has coevolved with its human host for at
least 58.000 years, and worldwide still half of the human
population is infected [1]. H. pylori infection leads to
chronic inflammation of the gastric mucosa, which remains
often without clinical symptoms. However, serious diseases
as peptic ulcer disease, mucosa-associated lymphoid tissue
(MALT) lymphoma, and gastric adenocarcinoma develop in
15 percent of the infected population [2]. Whereas H. pylori
infection triggers a vigorous immune response, resulting in
high titres of H. pylori-specific antibodies, this response is
not suﬃcient for eradication of the pathogen and when
remaining untreated with antibiotics, infection will remain
for life. Therefore, H. pylori is often regarded a model
organism for persistent bacterial infection in man [3].
H. pylori is heterogeneous and outcome of infection
depends on both bacterial virulence factors and host genet-
ics, as reviewed in [4]. Whereas appropriate host immune
responses lead to asymptomatic persistent colonization,
H. pylori-associated pathology is the result of aberrant
inflammation.
1.1. The Immune Response to H. pylori Infection. H. pylori
induces a strong innate immune response that involves
various components of the innate immune system, includ-
ing nucleotide-binding oligomerization domain protein I
(Nod1) [5] and secretion of antimicrobial peptides [6].
In addition, studies report that H. pylori induces pro-
inflammatory gene expression in host cells via Toll-like
receptor (TLR)2, TLR4, TLR5, and TLR9 [7–10]. However,
several of these reports present conflicting data and this area
requires further research, which should take into account
TLR expression dynamics [11] and the actual repertoire of
expressed TLR in the infected gastric mucosa in vivo. The
innate immune response to H. pylori results in inflammation
2 Journal of Biomedicine and Biotechnology
of the gastric epithelium (gastritis) and induces an influx
of neutrophils and other immune cell though the release of
chemokines and cytokines, as reviewed in [12], thereby being
essential for the initiation of an acquired immune response to
H. pylori.
Immunity to Helicobacter is dependent on T cells.
The murine H. felis infection model provides a useful
model resembling gastric pathological changes in human
H. pylori infection. H. felis infection of B and T cell-
deficient (RAG-1−/−) mice and T cell-deficient (TCRβδ−/−)
mice does not result in gastric pathology despite high levels
of colonization, whereas infection of B cell-deficient mice
results in severe gastric alteration, identical to those seen in
immunocompetent mice [13]. These results indicate that T
cells are required for protection against Helicobacter, but also
that gastric immune mediated damage is dependent on T
cells, and not by B cells or antibody secretion.
CD4+ T cells can be categorized according to their
cytokine-secretion profile and cytotoxic potential. There are
two main subsets of T helper (Th) cells. Th1 cells secrete
tumour necrosis factor (TNF) and interferon-γ (IFN-γ),
lyse antigen-loaded target cells through mechanisms that are
mediated by perforin or FAS (also known as CD95), and
elicit macrophage activation. Th2 cells secrete interleukin-4
(IL-4), IL-5, and IL-10, are involved in down regulation
of Th1cell-mediated inflammatory events, and facilitate
production of antibodies by B cells.
The host cytokine response is regarded an important
determinant in onset of gastritis and the development of
disease. Vaccination studies in diﬀerent mouse strains have
shown that, dependent on mouse strain or Helicobacter
species, both Th2 [14, 15] and Th1 [16, 17] cytokine
responses are involved in the adaptive immune response
against H. pylori and that protection from disease may
require the ability of the host to mount a balanced Th1/Th2
response upon infection.
Whereas the severity of gastritis due to innate immunity
influences the risk of disease, it seems that the pattern of
inflammation in the stomach determines which disease will
develop [2]: chronic antral-predominant inflammation is
associated with increased acid production and predisposes
tot duodenal ulceration, whereas corpus-predominant or
pan-gastritis is associated with reduced acid production and
predisposes to gastric ulceration and gastric adenocarci-
noma. Whether H. pylori-associated gastroduodenal disease
develops, or asymptomatic chronic gastritis, is related to the
predominant T-helper phenotype of the acquired immune
response that eventually arises upon infection. Human
gastric T cells in H. pylori infection have a predominant Th1
phenotype [18, 19], which is associated with pathology [20].
Dendritic cells (DC) in the gastric mucosa take up
antigens and migrate to nearby lymph nodes where they
activate naı¨ve T cells and orchestrate the subsequent immune
response [21]. In vitro, DC cultured in the presence of
H. pylori are activated and secrete cytokines, including
interleukin (IL)-6, IL-8, IL-10, IL-12, IL-1β, and TNFα [22,
23]. H. pylori-pulsed DC induce increased IL-2, IFN-γ, and
TNFα in CD4+CD45RA+ naı¨ve T cells, which is in agreement
with the Th1 cytokine profile produced by T cells from
gastric mucosal biopsies [18, 19, 24]. Virulence factors that
contribute to the predominance of Th1 responses in H. pylori
infection include the H. pylori neutrophil activating protein
(HP-NAP), which induces IL-12 secretion by neutrophils
and monocytes and strongly promotes Th1-skewing of
antigen-specific CD4+ T cells [25], and a plasticity region
locus jhp0947-jhp0949 that is associated with duodenal ulcer
disease [26]. In addition, the Th1/Th2 balance is influenced
by H. pylori genomic DNA recombination [27] and phase-
variable expression of LPS Lewis blood-group antigens which
bind to the DC receptor DC-SIGN [28], further enhancing
H. pylori capacity to adapt to the host immune system in
order to achieve persistent infection.
1.2. Polarization and Properties of CD4+ T Cells in H.
pylori-Associated Peptic Ulcer Disease. In H. pylori- infected
individuals, peptic ulcer disease (PUD) is associated with
Th1 polarization of gastric CD4+ T cell responses, whereas
uncomplicated chronic gastritis (UCG) is associated with a
mixed Th1/Th2 response [20]. T cell clones from the gastric
antral mucosa of patients with or without peptic ulcer display
a diﬀerent preferential antigen-specificity. Approximately
half of the H. pylori-reactive Th cell clones derived from pep-
tic ulcer patients were specific for the Cytotoxin-associated
protein (CagA), whereas approximately one forth of H.
pylori-reactive Th clones from nonulcer gastritis patients
were specific for H. pylori Urease [18, 20]. Upon antigen-
specific stimulation, over eighty percent of the H. pylori-
reactive Th cells from peptic ulcer disease patients showed
a polarized Th1 profile, with high production of IFN-γ and
no IL-4. In contrast, in non-ulcer gastritis patients about
two-third of the H. pylori-specific antral clones displayed a
mixed Th1/Th2 cytokine profile, whereas only one-third was
polarized to Th1 [20]. These results are in agreement with
several studies that indicate that Th1 polarization of the H.
pylori-specific T cell response is associated with more severe
disease [18, 19, 24, 26, 29, 30]. In the H. pylori-infected
gastric mucosa, IL-12 drives the Th1 signalling pathway [31].
The pathogenic capacity of polarized Th1 responses in H.
pylori infection is indirectly supported by the phenomenon
often referred to as “the African enigma” [32], that is,
despite a high prevalence of H. pylori infection in Africa,
peptic ulcer disease and gastric cancer are uncommon. The
notion that concurrent Th2 responses could reduce Th1-
mediated gastro-duodenal pathology and development of
gastric cancer is supported by the observation that coinfec-
tion of mice with H. felis and a natural murine helminth
(Heligmosomoides polygyrus) reduced Th1-mediated gastric
atrophy, which is regarded as a premalignant lesion [33].
Therefore, one possible explanation for the low prevalence
of H. pylori-associated diseases in Africa is that the endemic
high parasitic burden causes predominant Th2 responses
that protect H. pylori-individuals from developing peptic
ulcers and gastric cancer.
1.3. CD4+CD25+ Regulatory T Cells in H. Pylori-Induced
Gastric Inflammation. An accumulating body of evidence
indicates that CD4+CD25+ regulatory T cells (Treg) do
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not only prevent development of autoimmune diseases, but
also regulate pathogen- induced inflammation and disease,
including in H. pylori infection [34].
In mice, CD4+CD25+ Treg reduce gastric immu-
nopathology, despite increased H. pylori colonization of
the gastric mucosa [35], and in vitro suppress antigen-
specific proliferation of H. pylori-specific CD4+ T eﬀector
cells [36]. In vivo, depletion of CD4+CD25+Foxp3+ Treg in
H. pylori infected mice leads to severe gastritis, influx of
B cells, T cells, and macrophages into the gastric mucosa,
increased titers of H. pylori-specific IgG1, and IgG2c and,
subsequently, reduced bacterial load [37]. The mechanisms
of eﬀector T cell suppression by CD4+CD25+ Treg remain
to be elucidated, but they include CTLA-4-mediated anergy
[38] and TGF-β secretion [39]. Once CD4+ T cells are
rendered anergic by CD4+CD25+ Treg, the presence of these
Treg is not required to maintain hyporesponsiveness [40].
Also in humans, natural CD4+CD25+Foxp3+ Treg are
recruited during H. pylori infection and correlate with
increased bacterial colonization and mucosal TGF-β gene
expression [41]. When compared to adults, H. pylori-infected
children have increased numbers of Treg and increased
expression of the Treg-cytokines TGF-β and IL-10 and
lower level of gastritis, despite similar levels of H. pylori
colonization [39]. In addition, CD4+CD25+Foxp3+ Treg cell
numbers are increased in areas of duodenal gastric metapla-
sia in duodenal ulcer patients where they are localized in
CD4+ T cell aggregates [42]. Together, these results suggest
that H. pylori infection induces CD4+CD25+Foxp3+ Treg that
contribute to the asymptomatic persistent infection, seen in
the majority of people, and that individuals with inadequate
regulatory T cell responses will develop gastro-duodenal
pathology [43].
This profound role of regulatory T cells in outcome
of H. pylori infection may provide another explanation for
the “African enigma”: in endemic areas long-term helminth
infections induce a robust anti-inflammatory, regulatory T
cell network [44] that protects H. pylori-infected individuals
from peptic ulcer disease and gastric cancer.
2. H. pylori Infection, Molecular Mimicry, and
Gastric Autoimmunity
H. pylori infection is strongly associated with gastric autoim-
munity. Several clinical and epidemiological studies indicate
that most patients with autoimmune gastritis (AIG) have or
have had H. pylori infection [45]. AIG is characterized by
autoimmune- mediated destruction of the secretory glands
in the corpus of the stomach, leading to loss of gastric acid
producing parietal cells and zymogenic cells, referred to as
corpus atrophy. The end point of AIG is pernicious anemia
(PA) [46]. There are striking similarities between classical
AIG and H. pylori-induced corpus atrophic gastritis [47],
and histologically defined preclinical stages of AIG can be
successfully treated by H. pylori eradication [48–50].
H. pylori induces autoantibodies reactive with gastric
mucosal antigens in approximately half of the infected
individuals [51–55]. Gastric H+K+-ATPase, the proton pump
located in the secretory canaliculi of the parietal cells, is
the autoantigen that drives immunopathology in AIG [56].
H+K+-ATPase has also been identified as the single major
autoantigen in chronic H. pylori gastritis with corpus atrophy
[57].
In mice, H. pylori infection induces gastric autoanti-
bodies through mimicry between LPS Lewis blood-group
antigens and Lewis antigens on the glycosylated β-subunit
of H+K+-ATPase [58]. However, in humans, H. pylori-
associated anti-H+K+-ATPase autoantibodies are directed
against protein epitopes, and their formation does not
involve Lewis mimicry [47]. In humans, H. pylori infection
leads to the activation of gastric T cells, of which a
proportion is cross-reactive against both H. pylori peptide
antigens and H+K+-ATPase [59], and circulating antigastric
autoantibodies are not pathogenic themselves, but mark
ongoing T cell-mediated gastric autoimmunity.
2.1. Animal Models for Human AIG. Our knowledge of
the pathogenesis of human AIG is based largely on mouse
models of experimental autoimmune gastritis (EAIG) [60].
EAIG spontaneously develops in T cell receptor transgenic
(TCR-Tg) mice in which the CD4+ T cells express an αβTCR
that recognize an epitope of the H+K+-ATPase α-subunit
(630–641) [61] or in neonatally thymectomized mice [56]. In
EAIG and AIG, the gastric inflammatory infiltrate comprises
CD4+ and CD8+ T cells, macrophages and B cells [56], and
the histopathological lesions in mouse models are similar to
those observed in humans with chronic AIG [62, 63]. EAIG
is mediated by H+K+-ATPase-specific CD4+ T cells [64] and
gastritogenic T cell epitopes on both α and β subunits
on H+K+-ATPase have been identified [65–67]. In human
AIG, a proportion of autoreactive gastric T cells recognize
H+K+-ATPase epitopes identical or partly overlapping with
those in EAIG [68, 69]. The relevance of such partly con-
served epitopes in (E)AIG remains unclear, but availability
of an epitope for TCR recognition, rather than aﬃnity for
the TCR, enhances the gastritogenic potential of autoreactive
T cells [70]. EAIG can be induced by either Th1, Th2 or
Th17 (IL-17 secreting) cells specific for H+K+-ATPase [71].
However, a major role has been attributed to IFN-γ [72], and
gastric mucosa infiltrating Th1 cells in onset and pathology
of EAIG [73]. This is in concordance with our observation
that in AIG, the majority (87%) of H+K+-ATPase-specific
T cell clones produced IFN-γ upon stimulation with the
appropriate antigenic peptide epitope [69]. These striking
similarities between EAIG and AIG indicate that EAIG is
an excellent model for human AIG. Since EAIG is one of
the best studied animal models for human autoimmunity,
advances in this model may contribute to our knowledge
of organ-specific autoimmune disease in general. Recently,
the role of naturally occurring CD4+CD25+ Treg in Th1-,
Th2-, and Th17-mediated gastritis has been described [71]
and TGFβ-induced autoantigen-specific, Foxp3+ regulatory
T cells (iTreg) have been shown to prevent autoimmunity by
suppressing activation of autoantigen-presenting dendritic
cells [74]. Even if data in H. pylori model is still relatively
sparce, the balance between IL-12, IL-23, and Treg responses
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seems to play an important role in the type of inflammatory
responses in mouse models of inflammatory bowel disease.
The gastrointestinal tract of mammals is inhabited by many
diﬀerent species of commensal micro-organisms that exist in
a mutualistic relationship with the host. The colonization of
the small intestine of mice with a single commensal microbe,
such as segmented filamentous bacterium, was suﬃcient to
induce the appearance of Th cells able to produce IL-17
and IL-22 in the lamina propria with related activation
of inflammatory genes [75]. Using indeed mouse models
of H. hepaticus-induced T-cell dependent colitis, it was
demonstrated that IL-23 and not IL-12 is essential for the
development of a severe disease. Although IL-23 has been
implicated in the genesis of other inflammatory disorders via
the activation of IL-17-secreting Th cells, in this H. hepaticus
model of colitis, IL-17 in the absence of IFN-γ did not
appear suﬃcient to induce disease, the maximum intestinal
inflammation depending on both IFN-γ and IL-17 [76].
2.2. Gastric T Cells in AIG Patients without and with Con-
current H. pylori Infection. In AIG patients without evidence
of previous or actual H. pylori infection, large numbers of T
cells are present in the gastric mucosa [68]. Around 25% of
the corpus derived T cells recognized gastric H+K+-ATPase,
whereas only a few (3%) of the antral T cells proliferated
upon stimulation with this autoantigen. As in EAIG, in
which administration of depleting anti-CD4 antibodies but
not anti-CD8 antibodies reduces the incidence of gastritis
[64], all human H+K+-ATPase-specific T cell clones were
CD4+ [68, 69]. T cell proliferation to purified H+K+-ATPase
is dose-dependent and HLA Class II restricted, and involves
diﬀerent TCR Vβ rearrangements and submolecular epi-
topes, indicating that human AIG is driven by antigen-
specific polyclonal activation of autoreactive T cells, and not
due to expansion of a single- autoreactive T cell clone [68].
From AIG patients with a concurrent H. pylori infection,
gastric CD4+ T cells reactive to H+K+-ATPase and CD4+ T
cells reactive to H. pylori can be cloned, but also CD4+ T
cells that recognize both H+K+-ATPase and H. pylori antigens
[59]. Identification of these H. pylori/H+K+-ATPase-specific
T cells has provided a functional mechanism that can explain
the long known association between H. pylori infection and
corpus atrophic gastritis.
2.3. Antigen-Specificity and Cross-Reactivity of H. pylori/
H+K+-Atpase-Specific T Cells. A library of overlapping 15-
mer synthetic peptides, together comprising the entire
α and β subunits of human gastric H+K+-ATPase, was
used to identify the submolecular epitopes recognized by
H+K+-ATPase-specific and H. pylori/H+K+-ATPase-specific
CD4+ T cells from H. pylori- infected AIG patients [59,
68, 69]. Subsequently, candidate H. pylori epitopes were
predicted by alignment of identified H+K+-ATPase epitopes
with the genomes of the H. pylori J99 and 26695 strains,
taking into account the MHC class II peptide binding
motifs of each individual T cell donor [59]. The repertoire
of H+K+-ATPase α and β subunit epitopes recognized by
H+K+-ATPase-specific CD4+ T cell clones is similar in H.
pylori- infected and noninfected AIG patients [59, 69].
All H. pylori/H+K+-ATPase-cross-reactive T cells find their
autoantigenic epitope in the α subunit of H+K+-ATPase
[59], which is much longer (1034 amino acids) than the
β subunit (270 amino acids long) [69]. Surprisingly, none
of the identified H. pylori peptides recognized by the H.
pylori/H+K+-ATPase cross-reactive T cells belong to the
known immunodominant H. pylori proteins, that is, VacA,
CagA, and Urease, which have been identified as major
targets of gastric T cells in H. pylori- infected patients with
chronic antral gastritis [20] and peptic ulcer [18]. Instead,
the H. pylori peptide epitopes recognized by cross-reactive
T cells are predominantly derived from products of H.
pylori house-hold genes [59]. Antigen-specific stimulation
of H. pylori/H+K+-ATPase-cross-reactive T cells is HLA-DR
restricted [59]. H. pylori/H+K+-ATPase-reactive T cell clones,
derived from two diﬀerent donors that share the expression
of HLA-DRB1∗04 and recognize the same H+K+-ATPase
peptide, also find their bacterial epitope in the same H.
pylori. And vice versa, two T cell clones recognizing the same
H+K+-ATPase epitope, but derived from diﬀerent donors,
one expressing HLA-DRB1∗0301 and the other expressing
HLA-DRB1∗1303, find their cross-reactive bacterial peptide
in diﬀerent H. pylori proteins [59].
2.4. Cytokine Profile and Eﬀector Functions of Gastric T Cells in
Human AIG without and with Concurrent H. pylori Infection.
Upon activation with the appropriate antigenic peptide, all
H+K+-ATPase-reactive gastric T cell or H+K+-ATPase/H.
pylori-cross-reactive T cell clones from AIG patients have
a Th1 phenotype, characterized by production of IFN-γ
and neither IL-4 nor IL-5 [59, 68, 69]. After activation,
all the autoreactive and cross-reactive H+K+-ATPase-specific
Th clones were able to induce cell death via either Fas-
Fas ligand(FasL)-mediated apoptosis or perforin-mediated
cytotoxicity against target cells [59]. The expression of Fas
on gastric epithelial cells is increased by the Th1 cytokines
IFN-γ and TNFα [77] and Fas/FasL interactions contribute
to death of gastric epithelial cells [78].
Together, these observations are in agreement with at
least two possible scenario’s of the role of H. pylori infec-
tion in the onset or acceleration of gastric autoimmunity
[79]. In most infected individuals, as yet not completely
understood, interactions between H. pylori and the host
immune system lead to asymptomatic chronic inflammation
of the gastric mucosa, kept under control by CD4+CD25+
Treg. However, also apparently healthy individuals may
harbour H+K+-ATPase-autoreactive CD4+ T cells that have
escaped from negative selection in the thymus, as reflected
by the occasional presence of H+K+-ATPase-specific autoan-
tibodies [57]. In such individuals, H. pylori-driven chronic
Th1-mediated inflammation may be suﬃcient to abrogate
CD4+CD25+ Treg suppression, leading to activation of
H+K+-ATPase-specific CD4+ T cells and subsequent gastric
autoimmunity. A second scenario also involves thymic
escape by H+K+-ATPase-specific autoreactive T cells, but
in addition, genetics predisposes a host to develop gastric
autoimmunity if this host expresses particular HLA alleles
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Table 1: Immunodeficient mouse strains that develop spontaneous or induced lymphoma.
Strain Description Phenotype Ref
Perforin−/− Lack perforin Mice develop B cell lymphomas at 14–21
months
[92]
IFNg−/− Lack IFN-γ Mice develop predominantly T cell
lymphomas at 13–19 months
[93]
Perforin−/−IFNg−/− Lack perforin and IFN-γ
Mice develop B cell lymphomas similar to
those observed in perforin-deficient
mice, but with earlier onset and increased
frequency
[93]
Perforin−/−B2m−/− Lack perforin and MHC I
Mice develop B cell lymphomas similar to
those observed in perforin-deficient
mice, but with earlier onset and increased
frequency
[94]
Trail−/− Lack trail 25% of mice develop lymphomas later in
life (> 400 days)
[95]
IFNg−/− Lack IFN-γ
Increased susceptibility to
N-methyl-N-nitrosurea-induced
lymphomas
[97, 99]
IL12p35−/− Lack IL-12
Increased susceptibility to
N-methyl-N-nitrosurea-induced
lymphomas
[97]
P53+/−Perforin−/− Heterozygous for p53 and lack perforin Accelerated onset of B cell lymphomas [92]
IFNg−/−HTLVTax transgenic Lack IFN-γ and transgenic for Tax Accelerated onset of lymphomas or
leukemia
[98]
that can facilitate the presentation of both H+K+-ATPase
epitopes and H. pylori peptides [45, 79]. This second scenario
is supported by the significant association of increased risk
for development of PA with expression of HLA-DR2 /HLA-
DR4 or HLA-DR4/HLA-DR5 [80], and observations that
a substantial proportion of patients with PA are or were
infected with H. pylori [81, 82].
3. H. pylori Infection and MALT Lymphoma
Extranodal marginal zone B cell lymphoma of mucosa-
associated lymphoid tissue (MALT lymphoma) represents
the third commonest form of non-Hodgkin lymphoma [83,
84]. The most frequent site of MALT lymphomas is the
stomach, where they were first recognized as a distinct entity
[85]. A link of H. pylori infection with gastric MALT lym-
phoma was provided by the identification of H. pylori in the
majority of the lymphoma specimens [86]. H. pylori-related
low-grade gastric MALT lymphoma represents a model for
studying the interplay between chronic infection, immune
response, and lymphomagenesis. This lymphoma represents
the first described neoplasia susceptible of regression follow-
ing antibiotic therapy resulting in H. pylori eradication [87].
A prerequisite for lymphomagenesis is the development of
secondary inflammatory MALT induced by H. pylori. Tumor
cells of low-grade gastric MALT lymphoma (MALToma) are
memory B cells still responsive to diﬀerentiation signals, such
as CD40 costimulation and cytokines produced by antigen-
stimulated Th cells, and dependent for their growth on the
stimulation by H. pylori-specific T cells [88–91]. In early
phases, this tumor is sensitive to withdrawal of H. pylori-
induced T-cell help, providing an explanation for both the
tumor’s tendency to remain localized to its primary site and
its regression after H. pylori eradication.
3.1. H. pylori-Specific T Cells in Gastric MALT Lymphoma.
The analysis of the antigen-induced B-cell help exerted by
H. pylori-reactive gastric T-cell clones provided detailed
information on the molecular and cellular mechanisms
associated with the onset of low-grade gastric MALToma. In
the stomach of MALToma patients, a high percentage of Th
cells were specific for H. pylori (between 3% and 20% in
each case). In particular, 25% were specific for urease, 4%
for VacA, and none for CagA or HSP; 71% of Th clones
proliferated in response to H. pylori antigens, diﬀerent from
Urease, CagA, VacA, or HSP [91]. Each H. pylori-specific
Th clone derived from gastric MALToma produced IL-2 and
a variety of B-cell-stimulating cytokines, such as IL-4 and
IL-13 [91]. In vitro stimulation with the appropriate H.
pylori antigens induced H. pylori-specific Th clones derived
from gastric MALToma to express powerful help for B-cell
activation and proliferation [91]. B cells from MALToma
patients proliferate in response to H. pylori, but the B-cell
proliferation induced by H. pylori antigens was strictly T-cell-
dependent because it could not take place with H. pylori and
without T helper cells [91].
3.2. Eﬀector T Cell Functions in H. pylori-Associated MALT
Lymphoma. In chronic gastritis patients, either with or
without ulcer, the helper function towards B cells exerted
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Figure 1: Diﬀerent cytotoxic functions of T cells in H. pylori-related gastric autoimmunity and gastric lymphoma. T cells are essential for
defence against infection, but inappropriate Th responses can be harmful for the host. In susceptible individuals, H. pylori induces gastric
autoimmunity via molecular mimicry by the expansion of H. pylori-specific T cells that cross-react with H+K+-ATPase epitopes. Cross-
reactive T cells would result in destruction of gastric mucosa, by the long-lasting activation of both Fas-ligand (FasL)-induced apoptosis and
perforin-mediated cytotoxicity. Conversely, in a minority of infected patients, gastric H. pylori-specific Th cells display deficient cytotoxic
control (both perforin and Fas-Fas-ligand mediated) of B-cell growth. Such cytolytic defects, associated with the production of cytokines
with B-cell growth factor activity and the chronic delivery of costimulatory signals by Th cells, together with chronic exposure to H. pylori
antigens, would result in overgrowth of B cells, thus promoting the neoplastic B-cell transformation and the onset of gastric low-grade MALT
B-cell lymphoma.
by H. pylori antigen-stimulated gastric T-cell clones was
negatively regulated by the concomitant cytolytic killing
of B cells [18, 20]. In contrast, gastric T-cell clones from
MALToma were unable to downmodulate their antigen-
induced help for B-cell proliferation. Indeed, none of these
clones was able to express perforin-mediated cytotoxic-
ity against autologous B cells. Moreover, the majority of
Th clones from uncomplicated chronic gastritis induced
Fas-Fas ligand-mediated apoptosis in target cells, whereas
only a small fraction of H. pylori-specific gastric clones
from MALToma were able to induce apoptosis in tar-
get cells, including autologous B cells [91]. Both defec-
tive perforin-mediated cytotoxicity and poor ability to
induce Fas-Fas ligand-mediated apoptosis were restricted
to MALToma-infiltrating T cells, since H. pylori-specific Th
cells derived from the peripheral blood of the same patients
expressed the same cytolytic potential and proapoptotic
activity as that shown by Th cells from chronic gastritis
patients [91].
Accordingly, mice lacking T cell and NK cell cytotoxic
eﬀector pathways have also been shown to develop spon-
taneous tumors (Table 1) [92–101]. For example, mice that
lack perforin, a cytotoxic molecule used by cytotoxic cells
such as CD8+ T cells and NK cells to form membrane pores in
target cells, develop lymphomas with age. These spontaneous
lymphomas are of B cell origin, develop in older mice (>1
year of age) regardless of the mouse strain [94, 95], and,
when transplanted into WT mice, are rejected by CD8+ T
cells [94]. B cell lymphomas also arise in mice lacking both
perforin and β2 m, and tumor onset is earlier and occurs
with increased prevalence compared with mice lacking only
perforin. In addition, B cell lymphomas derived from mice
lacking both perforin and β2 m are rejected by either NK cells
or γδ T cells following transplantation to WT mice, rather
than by CD8+ T cells (as in tumors derived from mice lacking
only perforin), demonstrating that cell surface expression of
MHC class I molecules by tumor cells can be an important
factor in determining which eﬀector cells mediate immune
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protective eﬀects [96]. Intriguingly, mutations in the gene
encoding perforin have also been identified in subsets of
lymphoma patients [102], although it is not clear whether
this contributes to disease. Mice lacking the death-inducing
molecule TNF-related apoptosis-inducing ligand (TRAIL) or
expressing a defective mutant form of the death-inducing
molecule FasL have also been shown to be susceptible to
spontaneous lymphomas that develop with late onset [97,
98]. These aging studies have clearly demonstrated a critical
role for cytotoxic pathways in immunoregulation and/or
immunosuppression of spontaneous tumor development
in mice. The reason why gastric T cells of MALToma,
while delivering powerful help to B cells, are deficient
in mechanisms involved in the control of B-cell growth
still remains unclear. It has been shown that VacA toxin
inhibits antigen processing in APCs and T cells, but not
the exocytosis of perforin-containing granules of NK cells
[103, 104]. It is possible that, in some H. pylori-infected indi-
viduals, some bacterial components aﬀect the development
or the expression in gastric T cells of regulatory cytotoxic
mechanisms on B-cell proliferation, allowing exhaustive
and unbalanced B-cell help and lymphomagenesis to occur
[91, 105, 106].
4. Concluding Remarks
Helicobacter pylori is able to induce a huge variety of antigen-
specific T-cell responses in the stomach, due to host genetics,
age, sex, diﬀerent bacterial and environmental factors, or
other concomitant infections. The cytolytic eﬀector func-
tions of gastric H. pylori-specific T cells are extremely
diﬀerent between patients with autoimmune gastritis or
MALT lymphoma (Figure 1). In some patients, due to genetic
and environmental factors not yet fully elucidated, H. pylori
infection triggers an abnormal activation at gastric level of
cytotoxic, and proapoptotic cross-reactive T cells leading to
gastric autoimmunity via molecular mimicry. Conversely in
a minority of infected patients, H. pylori is able to induce the
development of specific T cells defective of both perforin-
and Fas ligand-mediated cytotoxicity, which consequently
promotes both B-cell overgrowth and exhaustive B-cell
proliferation, finally leading to the onset of low-grade gastric
MALT lymphoma.
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